GE Healthcare last week said that Jean-Luc Vanderheyden has joined the company to lead its Molecular Imaging business.
In his new role, Vanderheyden will report to the general manager, to be named at a later date.
Prior to GE Healthcare, Vanderheyden was the vice-president of research and development for Theseus Imaging and director of nuclear medicine research and development for Mallinckrodt/Tyco Healthcare. He was also a visiting associate professor in nuclear medicine at the University of Massachusetts Medical School.
Orchid Cellmark has appointed William J. Lutz to the newly created position of vice-president of information technology, the company said last week.
Prior to his appointment, Lutz, was chief information officer at Genencor International, a biotechnology company recently acquired by Danisco. He was also director of information management and technology at Bausch and Lomb. He has held positions at NCR, General Electric, Fischer Scientific, and the State University of New York at Binghamton.
Columbia University awarded the 2005 Louisa Gross Horwitz Prize to Ada Yonath, the university said last week.
Yonath is the Martin S. and Helen Kimmel Professor of Structural Biology and director of the Helen and Milton A. Kimmelman Center for Biomolecular Structure at the Weizmann Institute of Science in Israel.
The Louisa Gross Horwitz Prize has been awarded annually since 1967 for research in the fields of biology and biochemistry.
Yonath has received the National Institutes of Health Certificate of Distinction, the F.A.Cotton Medal for Excellence in Chemical Research, the 2000 Anfinsen Prize, the 2002 Harvey Prize for Natural Sciences, the 2002 Israel Prize for Chemical Research, the 2004 Massry Prize, and the 2004 Paul Karrer Gold Medal.
Yvonne Linney has left Caliper Life Sciences and is now head of molecular marketing for Bayer Diagnostics.
At Caliper, she was director of marketing. Before that, she held several directorial and managerial positions with Amersham Biosciences, now GE Healthcare.
DxS last week launched its EGFR Mutation Test Kit, the first of a line of oncology mutation test kits, the company said in a statement. The EGFR kit can perform quantitative detection of low-level tumor mutations and deletions in the EGFR gene with high specificity and sensitivity using AstraZeneca's ARMS technology combined with DxS' Scorpions signaling system, the statement said.
Genaco Biomedical Products last week said it had added avain flu testing capacity to its Templex diagnostic test, which can detect "all known strains" of the virus, along with 20 other respiratory pathogens, in four hours, the company said in a statement. Genaco can adapt the test, which uses Luminex beads for nucleic acid detection, to detect newly emerged virus strains within one week of their discovery, the statement said.